{"created":"2023-05-15T16:40:10.900036+00:00","id":14342,"links":{},"metadata":{"_buckets":{"deposit":"9cc35462-3b5b-4f63-8d32-e05f9f2dd36e"},"_deposit":{"created_by":2,"id":"14342","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"14342"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00014342","sets":["8:9"]},"author_link":["52175","52176","52174","52169","52177","52168","52179","52172","52171","52170","52178","52173"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2010-10","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"5","bibliographicPageEnd":"420","bibliographicPageStart":"418","bibliographicVolumeNumber":"77","bibliographic_titles":[{"bibliographic_title":"Joint, bone, spine : revue du rhumatisme"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"OBJECTIVE: The aim of this study was to evaluate whether serum COMP can estimate the therapeutic response of RA after 6 months of treatment with etanercept. METHODS: Forty-five RA patients receiving 25mg of etanercept twice a week for 6 months were registered in this prospective observational study. Clinical response to the therapy was evaluated by DAS 28. Laboratory variables- COMP, CRP, ESR, IgM-RF, MMP-3, and anti-CCP Ab -were assessed at baseline and after 6 months of treatment. We assessed the correlations between serum COMP and other variables and whether serum COMP is associated with DAS28 remission. RESULTS: Serum COMP correlated with DAS28-ESR (p<0.05, r=0.40) at baseline. At 6 months of etanercept treatment, 10 patients entered remission (DAS28-ESR<2.6) whereas the other 35 patients did not (DAS28-ESR>2.6). The decrement of serum COMP at 6 months was significant in the remission group (N=10) but not in the non-remission group (N=35). On the other hand, CRP, ESR and MMP-3 decreased at 6 months regardless of remission status. IgM-RF titer as well as anti-CCP Ab titer did not differ at 6 months. CONCLUSIONS: Serum COMP at baseline reflects clinical disease activity of RA. Serum COMP is a valuable serologic marker to identify the subset of RA patients achieving remission during treatment with etanercept.","subitem_description_type":"Abstract"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Joint Bone Spine, 77(5), pp.418-420; 2010","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Elsevier Masson SAS"}]},"item_2_relation_11":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"20864374","subitem_relation_type_select":"PMID"}}]},"item_2_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1016/j.jbspin.2010.01.016","subitem_relation_type_select":"DOI"}}]},"item_2_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"Copyright © 2010 Published by Elsevier Masson SAS"}]},"item_2_source_id_10":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AA11698054","subitem_source_identifier_type":"NCID"}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1297319X","subitem_source_identifier_type":"ISSN"}]},"item_2_source_id_8":{"attribute_name":"EISSN","attribute_value_mlt":[{"subitem_source_identifier":"17787254","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Kawashiri, Shin-Ya"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kawakami, Atsushi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ueki, Yukitaka"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Imazato, Takahiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Iwamoto, Naoki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Fujikawa, Keita"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Aramaki, Toshiyuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tamai, Mami"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nakamura, Hideki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Origuchi, Tomoki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ida, Hiroaki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Eguchi, Katsumi"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-12-22"}],"displaytype":"detail","filename":"JBS77_418.pdf","filesize":[{"value":"547.1 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"JBS77_418.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/14342/files/JBS77_418.pdf"},"version_id":"b466b375-996f-4020-a98e-954f17ce2772"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Cartilage oligomeric matrix protein","subitem_subject_scheme":"Other"},{"subitem_subject":"Etanercept","subitem_subject_scheme":"Other"},{"subitem_subject":"Rheumatoid arthritis","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6 months of etanercept treatment: Comparison with CRP, IgM-RF, MMP-3 and anti-CCP Ab.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6 months of etanercept treatment: Comparison with CRP, IgM-RF, MMP-3 and anti-CCP Ab."}]},"item_type_id":"2","owner":"2","path":["9"],"pubdate":{"attribute_name":"公開日","attribute_value":"2010-10-21"},"publish_date":"2010-10-21","publish_status":"0","recid":"14342","relation_version_is_last":true,"title":["Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6 months of etanercept treatment: Comparison with CRP, IgM-RF, MMP-3 and anti-CCP Ab."],"weko_creator_id":"2","weko_shared_id":2},"updated":"2023-05-15T18:47:58.534220+00:00"}